Cordis Launches SELUTION SLR Drug-Eluting Balloon in Japan for Peripheral Artery Disease Treatment

Key Takeaways

• Cordis launches SELUTION SLR PTA Drug-Eluting Balloon in Japan as the first sirolimus-eluting balloon for peripheral artery disease
• Clinical trial results show 81.5% primary patency and 93.8% freedom from reintervention at three years in complex patients
• The device provides Japanese physicians with a new treatment option for superficial femoral artery disease

---

TOKYO - Cordis, a leading interventional cardiovascular technology company, announced the commercial launch of its SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan on April 28, 2026.

First Sirolimus-Eluting Balloon in Japan

The SELUTION SLR represents a significant milestone as the first sirolimus-eluting balloon approved for use in Japan’s peripheral artery disease treatment market. This launch expands treatment options for Japanese physicians managing patients with superficial femoral artery (SFA) disease.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Strong Clinical Performance Data

The SELUTION SFA Japan clinical trial demonstrated robust long-term outcomes in a challenging patient population. Key results include:

• 81.5% primary patency maintained through three years
• 93.8% of patients remained free from reintervention at three years
• Durable clinical outcomes in complex patient cases

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Treatment Advantages

The drug-eluting balloon technology offers several advantages over traditional balloon angioplasty by delivering medication directly to the vessel wall during treatment. This approach aims to reduce restenosis rates and improve long-term vessel patency.

For Japan’s aging population, which faces increasing rates of peripheral artery disease, the SELUTION SLR provides physicians with an advanced interventional option that may reduce the need for repeat procedures.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Technology and Innovation

The SELUTION SLR utilizes sirolimus, an established drug with proven efficacy in preventing vessel re-narrowing. The balloon’s drug-coating technology ensures controlled medication delivery to target tissue while minimizing systemic exposure.

Cordis’s entry into the Japanese market with this innovative device strengthens the company’s global presence in interventional cardiovascular technologies and provides Japanese healthcare providers access to cutting-edge peripheral intervention tools.

---

Frequently Asked Questions

What conditions does the SELUTION SLR Drug-Eluting Balloon treat?

The SELUTION SLR is designed to treat peripheral artery disease, specifically targeting superficial femoral artery (SFA) disease by delivering sirolimus medication to prevent vessel re-narrowing after angioplasty.

When will the SELUTION SLR be available to patients in Japan?

The SELUTION SLR Drug-Eluting Balloon is now commercially available in Japan following Cordis’s launch announcement on April 28, 2026.

How does SELUTION SLR compare to standard balloon angioplasty?

Unlike standard balloons, SELUTION SLR delivers sirolimus medication directly to vessel walls during treatment, achieving 81.5% primary patency and 93.8% freedom from reintervention at three years in clinical trials.

Related coverage

• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease